重藥控股(000950.SZ):輔助生殖板塊2021年不存在重大業務調整
格隆匯3月7日丨重藥控股(000950.SZ)發佈股價異常波動公吿,公司關注到近日投資者關注輔助生殖、三胎概念。公司控股子公司湖北鼎康生物科技有限公司主要經營輔助生殖技術全過程的醫療耗材和器械。2020年,輔助生殖業務收入約佔公司全年營業收入0.6%,輔助生殖業務淨利潤約佔公司淨利潤6.8%,整體佔比較小;輔助生殖板塊2021年不存在重大業務調整,收入及利潤不存在較大波動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.